ABIVAX reported first-half 2026 operating cash use of €102.5 million, up from €66.6 million a year earlier. July's equity financing added €767.1 million net; the company projects its resources will fund operations into Q4 2029 under current assumptions.
At June 30, ABIVAX held €402.4 million in cash, cash equivalents and short-term investments. The company plans to submit a U.S. New Drug Application for obefazimod in ulcerative colitis by the end of 2026.
Sales and marketing expenses rose to €4.6 million from €1.5 million in the first half, and ABIVAX expects them to accelerate as U.S. commercialization preparations advance. Approval timing, additional regulatory requirements and launch uptake could affect capital needs before meaningful product revenue arrives; the July equity financing expanded the share base.
